Home › Companies › PROTAGONIST THERAPEUTICS INC. › 2024-2025
Compiled from SEC Form N-PX filings and PROTAGONIST THERAPEUTICS INC.’s Form 8-K, filed 2025-06-26 (Item 5.07 on EDGAR). Page generated 02 October 2026.
Explore PROTAGONIST THERAPEUTICS INC. in the interactive database Compare manager voting policies
These tallies are PROTAGONIST THERAPEUTICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2025-06-26 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Outcome |
|---|---|---|---|---|---|---|
| Elect Director: Harold E. Selick, Ph.D. | 44,822,907 | -- | -- | 9,210,036 | 1,918,517 | Majority: yes |
| Elect Director: Bryan Giraudo | 42,499,790 | -- | -- | 11,533,153 | 1,918,517 | Majority: yes |
| Proposal 2: To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers | 50,844,517 | 2,850,473 | 337,953 | -- | 1,918,517 | Majority: yes |
| Proposal 3: To ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for its fiscal year ending December 31, 2025 | 55,480,739 | 74,233 | 396,488 | -- | -- | Majority: yes |
Source: PROTAGONIST THERAPEUTICS INC., Form 8-K, filed with the SEC on 2025-06-26 — read the filing on EDGAR.
Each item below shows how the 301 asset managers that disclosed a PROTAGONIST THERAPEUTICS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 7 wordings of this item as funds reported it.
95% Majority: yes · of votes cast
PROTAGONIST THERAPEUTICS INC.’s own tally for this item (“Proposal 2: To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers”): 50,844,517 for, 2,850,473 against, per its Form 8-K filed 2025-06-26 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 61,928,760 outstanding shares: 82% for, 5% against (87% of the company cast a for/against vote).
The 298 asset managers below cast 94% of the shares they voted on this item FOR. Fund share totals are not shown for this item: fund-reported shares overlap across filings (an adviser and the funds it manages can each report the same shares), and here their sum exceeds the total votes cast at the meeting.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| BlackRock | 6,786,117 | 22,891 | 0 | 0 | For |
| RTW INVESTMENTS, LP | 5,685,801 | 0 | 0 | 0 | For |
| FARALLON CAPITAL MANAGEMENT LLC | 4,690,516 | 0 | 0 | 0 | For |
| Vanguard | 4,331,314 | 2,866 | 0 | 0 | For |
| State Street | 3,875,469 | 17,908 | 0 | 0 | For |
| Deep Track Capital, LP | 3,250,000 | 0 | 0 | 0 | For |
| BVF INC/IL | 2,575,015 | 0 | 0 | 0 | For |
| Fidelity | 2,344,224 | 0 | 0 | 0 | For |
| T. Rowe Price | 2,114,029 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 1,427,914 | 0 | 0 | 0 | For |
| American Century | 0 | 1,323,661 | 0 | 0 | Against |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 1,120,164 | 0 | 0 | 0 | For |
| Charles Schwab | 1,070,918 | 0 | 0 | 0 | For |
| Invesco | 0 | 931,072 | 0 | 0 | Against |
| ADAR1 Capital Management, LLC | 843,380 | 0 | 0 | 0 | For |
| Wellington | 772,201 | 0 | 0 | 0 | For |
| Lynx1 Capital Management LP | 733,014 | 0 | 0 | 0 | For |
| Eversept Partners, LP | 669,798 | 0 | 0 | 0 | For |
| JPMorgan | 607,997 | 0 | 0 | 0 | For |
| Northern Trust | 571,691 | 526 | 0 | 0 | For |
| PERCEPTIVE ADVISORS LLC | 547,562 | 0 | 0 | 0 | For |
| PICTET ASSET MANAGEMENT SA | 508,131 | 0 | 0 | 0 | For |
| Woodline Partners LP | 480,634 | 0 | 0 | 0 | For |
| BNP Paribas Asset Management Holding S.A. | 0 | 354,697 | 0 | 0 | Against |
| PRINCIPAL GLOBAL INVESTORS | 351,090 | 0 | 0 | 0 | For |
Showing the 25 largest of 298 asset managers. See all 298 in the interactive database.
Combines 2 wordings of this item as funds reported it.
99.8% Majority: yes · of votes cast
PROTAGONIST THERAPEUTICS INC.’s own tally for this item (“Proposal 3: To ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for its fiscal year ending December 31, 2025”): 55,480,739 for, 74,233 against, per its Form 8-K filed 2025-06-26 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 61,928,760 outstanding shares: 90% for, 0.2% against (90% of the company cast a for/against vote).
The 90 asset managers below cast 99.7% of the shares they voted on this item FOR (17,546,862 for, 40,199 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| BlackRock | 4,833,296 | 0 | 0 | 0 | For |
| Vanguard | 4,187,821 | 0 | 0 | 0 | For |
| Fidelity | 1,813,575 | 0 | 0 | 0 | For |
| State Street | 1,363,502 | 0 | 0 | 0 | For |
| T. Rowe Price | 923,420 | 0 | 0 | 0 | For |
| American Century | 655,557 | 0 | 0 | 0 | For |
| Charles Schwab | 506,757 | 0 | 0 | 0 | For |
| Invesco | 392,327 | 0 | 0 | 0 | For |
| Hartford | 195,842 | 0 | 0 | 0 | For |
| Equitable | 172,579 | 0 | 0 | 0 | For |
| JPMorgan | 162,064 | 0 | 0 | 0 | For |
| TIAA | 146,001 | 0 | 0 | 0 | For |
| Victory Capital | 132,533 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 126,420 | 0 | 0 | 0 | For |
| First Trust | 111,012 | 0 | 0 | 0 | For |
| Lincoln Financial | 107,476 | 0 | 0 | 0 | For |
| Jackson National | 104,036 | 0 | 0 | 0 | For |
| John Hancock | 94,021 | 0 | 0 | 0 | For |
| Northwestern Mutual | 89,634 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 85,963 | 0 | 0 | 0 | For |
| HUSSMAN INVESTMENT TRUST | 84,000 | 0 | 0 | 0 | For |
| CARILLON SERIES TRUST | 81,994 | 0 | 0 | 0 | For |
| BNY Mellon | 66,306 | 0 | 0 | 0 | For |
| DRIEHAUS MUTUAL FUNDS | 65,647 | 0 | 0 | 0 | For |
| Voya | 62,413 | 0 | 0 | 0 | For |
Showing the 25 largest of 90 asset managers. See all 90 in the interactive database.
Combines 6 wordings of this item as funds reported it.
83% Majority: yes · of votes cast
PROTAGONIST THERAPEUTICS INC.’s own tally for this item (“Elect Director: Harold E. Selick, Ph.D.”): 44,822,907 for, 9,210,036 withheld, per its Form 8-K filed 2025-06-26 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 61,928,760 outstanding shares: 72% for, 15% withheld (87% of the company cast a for/withheld vote).
The 89 asset managers below cast 100% of the shares they voted on this item FOR (14,951,260 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| BlackRock | 4,414,634 | 0 | 418,662 | 0 | For |
| Vanguard | 4,184,945 | 0 | 2,876 | 0 | For |
| Fidelity | 1,813,575 | 0 | 0 | 0 | For |
| State Street | 1,361,689 | 0 | 1,813 | 0 | For |
| T. Rowe Price | 923,420 | 0 | 0 | 0 | For |
| American Century | 0 | 0 | 655,557 | 0 | Abstain |
| Charles Schwab | 506,757 | 0 | 0 | 0 | For |
| Invesco | 392,327 | 0 | 0 | 0 | For |
| Hartford | 195,842 | 0 | 0 | 0 | For |
| Equitable | 107,599 | 0 | 64,980 | 0 | For |
| JPMorgan | 162,064 | 0 | 0 | 0 | For |
| TIAA | 0 | 0 | 146,001 | 0 | Abstain |
| Victory Capital | 0 | 0 | 132,533 | 0 | Abstain |
| Columbia Threadneedle | 126,420 | 0 | 0 | 0 | For |
| First Trust | 0 | 0 | 111,012 | 0 | Abstain |
| Lincoln Financial | 65,839 | 0 | 41,637 | 0 | For |
| Jackson National | 0 | 0 | 104,036 | 0 | Abstain |
| John Hancock | 49,699 | 0 | 44,322 | 0 | For |
| Northwestern Mutual | 89,634 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 85,963 | 0 | 0 | 0 | For |
| HUSSMAN INVESTMENT TRUST | 84,000 | 0 | 0 | 0 | For |
| CARILLON SERIES TRUST | 0 | 0 | 81,994 | 0 | Abstain |
| BNY Mellon | 0 | 0 | 66,306 | 0 | Abstain |
| DRIEHAUS MUTUAL FUNDS | 0 | 0 | 65,647 | 0 | Abstain |
| Voya | 62,413 | 0 | 0 | 0 | For |
Showing the 25 largest of 89 asset managers. See all 89 in the interactive database.
Combines 6 wordings of this item as funds reported it.
79% Majority: yes · of votes cast
PROTAGONIST THERAPEUTICS INC.’s own tally for this item (“Elect Director: Bryan Giraudo”): 42,499,790 for, 11,533,153 withheld, per its Form 8-K filed 2025-06-26 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 61,928,760 outstanding shares: 69% for, 19% withheld (87% of the company cast a for/withheld vote).
The 88 asset managers below cast 100% of the shares they voted on this item FOR (13,646,880 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| BlackRock | 4,414,634 | 0 | 418,662 | 0 | For |
| Vanguard | 4,184,943 | 0 | 2,878 | 0 | For |
| Fidelity | 1,813,575 | 0 | 0 | 0 | For |
| State Street | 1,361,689 | 0 | 1,813 | 0 | For |
| T. Rowe Price | 923,420 | 0 | 0 | 0 | For |
| American Century | 0 | 0 | 655,557 | 0 | Abstain |
| Charles Schwab | 0 | 0 | 506,757 | 0 | Abstain |
| Invesco | 0 | 0 | 392,327 | 0 | Abstain |
| Hartford | 195,842 | 0 | 0 | 0 | For |
| Equitable | 107,599 | 0 | 64,980 | 0 | For |
| JPMorgan | 162,064 | 0 | 0 | 0 | For |
| TIAA | 0 | 0 | 146,001 | 0 | Abstain |
| Victory Capital | 0 | 0 | 132,533 | 0 | Abstain |
| Columbia Threadneedle | 0 | 0 | 126,420 | 0 | Abstain |
| First Trust | 0 | 0 | 111,012 | 0 | Abstain |
| Lincoln Financial | 65,839 | 0 | 41,637 | 0 | For |
| Jackson National | 0 | 0 | 104,036 | 0 | Abstain |
| John Hancock | 49,699 | 0 | 44,322 | 0 | For |
| Northwestern Mutual | 68,885 | 0 | 20,749 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 85,963 | 0 | 0 | 0 | For |
| CARILLON SERIES TRUST | 0 | 0 | 81,994 | 0 | Abstain |
| BNY Mellon | 0 | 0 | 66,306 | 0 | Abstain |
| DRIEHAUS MUTUAL FUNDS | 0 | 0 | 65,647 | 0 | Abstain |
| Voya | 0 | 0 | 62,413 | 0 | Abstain |
| Principal | 529 | 0 | 57,887 | 0 | Abstain |
Showing the 25 largest of 88 asset managers. See all 88 in the interactive database.
Ranked by the number of PROTAGONIST THERAPEUTICS INC. shares each manager voted on the most widely held ballot item of the 2024-2025 meeting, shown as a share of the 61,928,760 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | BlackRock | 10.99% |
| 2 | RTW INVESTMENTS, LP | 9.18% |
| 3 | FARALLON CAPITAL MANAGEMENT LLC | 7.57% |
| 4 | Vanguard | 7.00% |
| 5 | State Street | 6.29% |
| 6 | Deep Track Capital, LP | 5.25% |
| 7 | BVF INC/IL | 4.16% |
| 8 | Fidelity | 3.79% |
| 9 | T. Rowe Price | 3.41% |
| 10 | GEODE CAPITAL MANAGEMENT, LLC | 2.31% |
Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).
| Holder | % outstanding | Disclosure |
|---|---|---|
| Entities affiliated with BlackRock, Inc. | 15.96% | DEF14A |
| BlackRock | 15.72% | 13F |
| Entities affiliated with Farallon Partners, L.L.C. | 10.03% | DEF14A |
| Farallon Partners, L.L.C. | 9.89% | 13G |
| Entities affiliated with RTW Investments, L.P. | 8.58% | DEF14A |
| RTW Investments, LP | 8.17% | 13G |
| Vanguard Group | 6.91% | 13F |
| Entities affiliated with The Vanguard Group | 6.81% | DEF14A |
| Vanguard Portfolio Management | 5.70% | 13G |
| Entities affiliated with Deep Track Capital, LP | 5.25% | DEF14A |
Percentages above are of 61,928,760 shares outstanding, as reported by PROTAGONIST THERAPEUTICS INC. on its Form 10-Q dated 2025-03-31 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from PROTAGONIST THERAPEUTICS INC.’s 10-Q dated 2025-03-31. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.
At PROTAGONIST THERAPEUTICS INC.'s shareholder meeting held 2025-06-20, in the 2024-2025 proxy season, 301 asset managers reported how they voted on 4 ballot items in their SEC Form N-PX filings, covering 1,449 separate fund positions. On the most widely held item on that ballot — To approve, on a non-binding, advisory basis, the compensation of the Company's named executive… — FOR was 95% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: PROTAGONIST THERAPEUTICS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2025-06-26.
PROTAGONIST THERAPEUTICS INC. proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.